LipidProject ID: 673467
Financiado con arreglo a:
H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy
The untapped potential of omega-3; from fish oil to healthy bowels
Detalles del proyecto
Coste total:EUR 71 429
Aportación de la UE:EUR 50 000
Tema(s):BG-12-2014-1 - Supporting SMEs efforts for the development - deployment and market replication of innovative solutions for blue growth
Convocatoria de propuestas:H2020-SMEINST-1-2014See other projects for this call
Régimen de financiación:SME-1 - SME instrument phase 1
Europe's consumers are increasingly requesting products that are organically and sustainably produced. At the same time, Europe has been lacking incentives to develop and bring to markets new marine products, without increasing pressure on natural resources.
The innovation in question; a natural, sustainably produced medicine based on marine oils, addresses these challenges. It is based on the discovery that omega-3 oils have proven to have laxative effects. It offers parents and pediatricians a pain-free alternative to other pharmaceutical products, in a market where no new products have been introduced for decades. The innovation also paves the way for the full utilization of marine products, demonstrating that by-products can be of high value for other industries, including the pharmaceutical sector.
The aim of the applicant is to develop this innovation all the way towards a market-ready, licensed pharmaceutical product. The pharmaceutical industry is one of the largest industries in the world in regards to revenues. Over 100 million people worldwide, suffer from constipation. The active ingredient of the innovation product would be a new and a unique addition to this growing market.
The applicant seeks support to be able to obtain a solid analysis of the market potential for the innovation. If successfully brought to markets, it will reach the milestone of being the first non-generic, registered drug, tested in clinical trials in humans that was discovered, developed and produced in one of Europe's most peripheral corners, Iceland.
Aportación de la UE: EUR 50 000